{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T04:16:45Z","timestamp":1765772205411},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1999,9,1]],"date-time":"1999-09-01T00:00:00Z","timestamp":936144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[1999,9]]},"DOI":"10.1016\/s0165-5728(99)00039-9","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T19:43:14Z","timestamp":1027626194000},"page":"142-149","source":"Crossref","is-referenced-by-count":62,"title":["Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing\u2013remitting multiple sclerosis"],"prefix":"10.1016","volume":"99","author":[{"given":"Maria Ida","family":"Gobbini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy D","family":"Richert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry F","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0165-5728(99)00039-9_BIB1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","article-title":"Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann. Int. Med."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","article-title":"The Canadian cooperative trial of cyclophosphamide and plasmaexchange in progressive multiple sclerosis","volume":"337","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB3","unstructured":"Chabner, B.A., Allegra, C.J., Curt, G.A., et al., 1996. Antineoplastic agents, In: Goodman, Gilman (Eds.), The Pharmacological Basis of Thrapeutics, Chapter 51, 9th edition, Mcgraw-Hill."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02333857","article-title":"et al. Cyclophosphamide in relapsing remitting multiple sclerosis","volume":"11","author":"D'Andrea","year":"1990","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB5","unstructured":"De Carli, C., Stone, L.A., Frank, J.A., et al. A semiautomated statistical method for quantifying white matter lesions on MRI in patients with multiple sclerosis, Mult Scler, in press."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB6","first-page":"173","article-title":"Cyclophosphamide","volume":"214","author":"Drachman","year":"1977","journal-title":"J. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/archneur.1987.00520200027013","article-title":"Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs. non-maintenance therapy","volume":"44","author":"Goodkin","year":"1987","journal-title":"Arch. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-065X.1995.tb00066.x","article-title":"Immunologic mechanism and therapy in multiple sclerosis","volume":"144","author":"Hafler","year":"1995","journal-title":"Immunol. Rev."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.410290515","article-title":"Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing\u2013remitting multiple sclerosis: implications for clinical trials and natural history","volume":"29","author":"Harris","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis","volume":"308","author":"Hauser","year":"1983","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0002-9343(90)90367-M","article-title":"Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide","volume":"89","author":"Hoffman","year":"1990","journal-title":"Am. J. Med."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB13","first-page":"A146","article-title":"Treatment of progressive multiple sclerosis with pulse cyclophosphamide\/methylprednisolone: response to therapy is linked to duration of progressive disease","volume":"50","author":"Hohol","year":"1998","journal-title":"Nurology"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing\u2013remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneur.1988.00520250033014","article-title":"Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis","volume":"45","author":"Killian","year":"1988","journal-title":"Arch. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0049-0172(83)90016-1","article-title":"Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic disease","volume":"12","author":"Kovarsky","year":"1983","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jnnp.54.12.1055","article-title":"Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study","volume":"54","author":"Likosky","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/096120339700600307","article-title":"Side-effects of intravenous cyclophosphamide pulse therapy","volume":"6","author":"Martin","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB19","unstructured":"Martindale. The Extra Pharmacopoeia, 31st edition, Royal Pharmaceutical Society, London, 1996, pp. 554\u2013557."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ana.410320609","article-title":"Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis","volume":"32","author":"McFarland","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB21","first-page":"S31","article-title":"Therapeutic options for critically ill patients suffering from progressive lupus nephritis or Goodpasture's syndrome","volume":"53","author":"Merkel","year":"1998","journal-title":"Kidney International"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(69)91788-7","article-title":"Cyclophosphamide in multiple sclerosis","volume":"1","author":"Millac","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF02337446","article-title":"Twenty-four-month follow-up of multiple sclerosis patients treated with cyclophosphamide","volume":"11","author":"Millefiorini","year":"1990","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB24","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1002\/ana.410360720","article-title":"Magnetic resonance in monitoring the treatemnt of multiple sclerosis","volume":"36","author":"Miller","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/brain\/121.1.3","article-title":"The role of magnetic resonance techniques in understanding and managing multiple sclerosis","volume":"121","author":"Miller","year":"1998","journal-title":"Brain"},{"issue":"8918","key":"10.1016\/S0165-5728(99)00039-9_BIB26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(94)91339-0","article-title":"Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis","volume":"344","author":"Moreau","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.165.3889.191","article-title":"Cyclophosphamide: Effect on Experimental Allergic Encephalomyelitis in Lewis Rats","volume":"165","author":"Paterson","year":"1969","journal-title":"Science"},{"issue":"1","key":"10.1016\/S0165-5728(99)00039-9_BIB28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003088-199834010-00004","article-title":"Optimisation of cyclophosphamide therapy in systemic vasculitis","volume":"34","author":"Richmond","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/S0165-5728(99)00039-9_BIB29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2165\/00003495-199754030-00005","article-title":"Recognition and management of Systemic Lupus Erythematosus","volume":"54","author":"Schroeder","year":"1997","journal-title":"Drug"},{"issue":"8914","key":"10.1016\/S0165-5728(99)00039-9_BIB30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/S0165-5728(99)00039-9_BIB31","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1212\/WNL.49.3.862","article-title":"Characterization of MRI response to treatment with interferon beta 1-b: contrast-enhancing MRI lesion frequency as a primary outcome measure","volume":"49","author":"Stone","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.410370511","article-title":"The effect of Interferon-beta on blood\u2013brain barrier disruptions demonstreted by contrast-enhanced magnetic resonance imaging in relapsing\u2013remitting multiple sclerosis","volume":"37","author":"Stone","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB33","unstructured":"Stone, L.A., Frank, J.A., McFarland, H.F., Private communication."},{"key":"10.1016\/S0165-5728(99)00039-9_BIB34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF01733202","article-title":"Blut\u2013Hirnschranke und Penetration von Zytostatika","volume":"63","author":"Unger","year":"1985","journal-title":"Klin. Wochenschr."},{"issue":"5","key":"10.1016\/S0165-5728(99)00039-9_BIB35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1212\/WNL.43.5.910","article-title":"Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group","volume":"43","author":"Weiner","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/S0165-5728(99)00039-9_BIB36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00127893-199705000-00005","article-title":"Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide","volume":"3","author":"Weinstock-Guttman","year":"1997","journal-title":"The Neurologist"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572899000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572899000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T13:16:15Z","timestamp":1579094175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572899000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["S0165572899000399"],"URL":"https:\/\/doi.org\/10.1016\/s0165-5728(99)00039-9","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[1999,9]]}}}